Xi Venture Capital participates in the tens of millions of RMB Series A financing of Yingda Tong

　　Recently, Xicheng Venture Capital, together with well-known investment institutions such as Junshi Venture Capital and Jishi Capital, completed tens of millions of RMB in Series A financing for Wuxi Yingdatong Medical Co., Ltd. (hereinafter referred to as "Yingdatong") and helped it land in Wuxi. The funds raised in this round of financing will be used to support the design validation and clinical trials of the series of disposable vascular intervention robots from Innovent Medical. At the same time, Innovent will further increase its research and development investment and launch more original devices around the clinical needs of vascular disease treatment.

　　Yingdatong focuses on the research and production of fully consumable vascular intervention surgical robots, first conquering the nerve intervention surgery known as the "pearl on the crown of intervention surgery". Compared to traditional surgical robots, the product advantages of Innovent are obvious. Its independently developed unique catheter design and supporting electromechanical system do not require a trade-off between thrust, torque, and flexibility, which can help doctors reach the affected area more conveniently through tortuous blood vessels during surgery. It also has the potential to provide remote surgery, reducing the ionizing radiation and bone system disease hazards of traditional vascular surgery on the operator. Meanwhile, the fully consumable design eliminates the need for hospitals to purchase fixed equipment, greatly reducing their procurement threshold.